News >

[Fam-] Trastuzumab Deruxtecan Elicits Responses in Advanced HER2+ Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, May 08, 2019

Jose Baselga, MD

José Baselga, MD

The antibody-drug conjugate (ADC) [fam-] trastuzumab deruxtecan (DS-8201) demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine (T-DM1; Kadcyla), according to topline findings from the phase II DESTINY-BreastO1 study.1

Fifty percent of patients experienced a grade ≥3 AE and 19% had a serious AE; this included 2 earlier reported cases of grade 5 treatment-related pneumonitis. Additionally, reported cases of interstitial lung disease or pneumonitis in the clinical development program for this agent are evaluated by an independent adjudication committee. A formal monitoring and management program is also in place to help determine the risk of these toxicities.


  1. Trastuzumab Deruxtecan Demonstrated Clinically-Meaningful Response in Patients With Refractory HER2-Positive Metastatic Breast Cancer, a Population With High Unmet Need. AstraZeneca. Published May 8, 2019. Accessed May 8, 2019.
  2. Doi T, Iwata H, Tsurutani J, et al. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors. J Clin Oncol. 2017;35(suppl; abstr 108).
  3. Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study [published online ahead of print April 29, 2019]. Lancet Oncol. doi: 10.1016/S1470-2045(19)30097-X.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication